Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non‐biologic systemic therapies

KJM has received honoraria from Janssen, LEO Pharma, Lilly and Novartis. ADB consults and lectures for Abbvie, Amgen, Boehringer Ingelheim, Celgene, Janssen, Lilly, Novartis and Pfizer. JNWN has received honoraria for advisory boards and lectures at sponsored symposia together with grants for research in the past 5 years from AbbVie, Amgen, Celgene, Janssen, Lilly, Novartis, and Pfizer. CEK has received honoraria and/or research funding from AbbVie, Celgene, Galderma, GSK-Stiefel, Janssen, Johnson & Johnson, LEO Pharma, Lilly, Novartis, Pfizer and UCB Pharma. KM has received honoraria from Lilly and UCB Pharma. CEMG has received honoraria and/or research grants from Abbvie, Actelion, Almirall, Amgen, Celgene, Galderma, LEO Pharma, GSK-Stiefel, Janssen, Lilly, MSD, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals and UCB Pharma. NJR reports grants from PSORT industrial partners as listed (http://www.psort.org.uk/); other research grants from GSK-Stiefel and Novartis; and other income to Newcastle University from Almirall, Amgen, Janssen, Novartis, Sanofi Genzyme Regeneron and UCB Pharma Ltd for lectures/attendance at advisory boards. All other authors (ML; HA; MMS; ACG; ADO) declare no conflicts. Data presented in this paper can be made available by application. Please follow the steps under ‘Data Requests’ on the BADBIR website: http://www.badbir.org/Publications/.